Rani Therapeutics Holdings (RANI) EBITDA (2020 - 2026)
Rani Therapeutics Holdings (RANI) posted quarterly EBITDA of -$8.3 million for Q1 2026, up 30.58% year-over-year from -$6.4 million in Q1 2025, and up 2.3% quarter-over-quarter from -$8.5 million in Q4 2025.
Rani Therapeutics Holdings (RANI) EBITDA (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings' EBITDA history runs 7 years deep, the most recent figure standing at -$8.3 million for Q1 2026.
- In Q1 2026, EBITDA rose 30.58% year-over-year to -$8.3 million; the TTM figure through Mar 2026 stood at -$34.6 million (up 32.48% YoY), while the FY2025 annual figure was -$38.3 million, up 28.14% from the prior year.
- EBITDA for Q1 2026 stood at -$8.3 million, up from -$8.5 million in the prior quarter.
- The five-year high for EBITDA was -$7.3 million in Q3 2025, with the low at -$18.3 million in Q2 2023.
- The 5-year median for EBITDA is -$13.8 million (2022), against an average of -$13.5 million.
- The sharpest annual moves came in 2022 and 2025: EBITDA plunged 201.39% in 2022, then surged 42.94% in 2025.
- Rani Therapeutics Holdings' EBITDA stood at -$17.5 million in 2022, then rose by 23.16% to -$13.4 million in 2023, then decreased by 11.34% to -$15.0 million in 2024, then jumped by 42.94% to -$8.5 million in 2025, then increased by 2.3% to -$8.3 million in 2026.
- Business Quant data shows RANI's EBITDA at -$8.3 million in Q1 2026, -$8.5 million in Q4 2025, and -$7.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Rani Therapeutics Holdings | 160.33 Mn | 160.33 Mn | - | -8.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.83 Mn |
| Mar 31, 2026 | -8.34 Mn |
| Dec 31, 2025 | -8.54 Mn |
| Sep 30, 2025 | -7.26 Mn |
| Jun 30, 2025 | -10.51 Mn |
| Mar 31, 2025 | -12.01 Mn |
| Dec 31, 2024 | -14.96 Mn |
| Sep 30, 2024 | -11.80 Mn |
| Jun 30, 2024 | -12.52 Mn |
| Mar 31, 2024 | -14.03 Mn |
| Dec 31, 2023 | -13.43 Mn |
| Sep 30, 2023 | -17.86 Mn |
| Jun 30, 2023 | -18.29 Mn |
| Mar 31, 2023 | -16.52 Mn |
| Dec 31, 2022 | -17.48 Mn |
| Sep 30, 2022 | -16.34 Mn |
| Jun 30, 2022 | -15.85 Mn |
| Mar 31, 2022 | -13.78 Mn |
| Dec 31, 2021 | -13.36 Mn |
| Sep 30, 2021 | -27.78 Mn |